AR and neoplasm: Recently, the challenge of molecular stratification of cancer patient through liquid biopsy using circulating tumor DNA27 has allowed qualifying plasma AR as a minimally invasive genetic biomarker of clinical outcome and resistance to abiraterone or enzalutamide3.